^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Lumakras (sotorasib) (KRAS G12C inhibitor) + JSI-1187 (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
429 / 24 - Efficacy of JSI-1187 or VIC-1911 in combination with KRAS G12C inhibitors for the treatment of KRAS G12C-mutated non-small cell lung cancer and colorectal cancer
Published date:
03/15/2023
Excerpt:
To evaluate the effects of the concomitant inhibition of JSI-1187 or VIC-1911 with sotorasib, we assessed the response in 4 G12C-mutated cell lines, including two NSCLC and two CRC…the antitumor growth effect of JSI-1187 and sotorasib was significantly better than the combination of the MEK inhibitor, trametinib, and sotorasib. Greater inhibition of tumor growth was also observed for the combination vs. monotherapy in H358 and SW837 CRC- bearing mouse models...the combination of JSI-1187 and sotorasib demonstrated a significant increase in tumor growth inhibition in a CRC PDX model.
